Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Ranging and Efficacy Study of Ixekizumab in Moderate-to-Severe Psoriasis
2010-018948-14Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriasis comparing Ixekizumab dose-ranging with Placebo (2 arms). Primary endpoints: PASI 75 response at Week 12 and Percentage PASI improvement. Started May 2010; status: completed.
02
Drugs
ixekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2010-018948-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018948-14.